S211: EFFICACY AND SAFETY OF ROPEGINTERFERON ALFA-2B FOR PRE-FIBROTIC PRIMARY MYELOFIBROSIS AND DIPSS LOW/INTERMEDIATE-1 RISK MYELOFIBROSIS: UPDATED RESULTS AND GENOMIC CHARACTERISTICS

• Harry Gill,
• Lester Au,
• Dorothy Tsai,
• Man Kit Garret Leung,
• Rita Yim,
• Lynn Chin,
• Vivian LI,
• Paul Lee,
• Chung Fung Albert Sin,
• Hsin-An Hou,
• Chih-Cheng Chen,
• Yok Lam Kwong

Affiliations

Harry Gill

1 LKS Faculty of Medicine, the University of Hong Kong, Department of Medicine, Hong Kong, Hong Kong

Lester Au

1 LKS Faculty of Medicine, the University of Hong Kong, Department of Medicine, Hong Kong, Hong Kong

Dorothy Tsai

1 LKS Faculty of Medicine, the University of Hong Kong, Department of Medicine, Hong Kong, Hong Kong

Man Kit Garret Leung

1 LKS Faculty of Medicine, the University of Hong Kong, Department of Medicine, Hong Kong, Hong Kong

Rita Yim

1 LKS Faculty of Medicine, the University of Hong Kong, Department of Medicine, Hong Kong, Hong Kong

Lynn Chin

1 LKS Faculty of Medicine, the University of Hong Kong, Department of Medicine, Hong Kong, Hong Kong

Vivian LI

1 LKS Faculty of Medicine, the University of Hong Kong, Department of Medicine, Hong Kong, Hong Kong

Paul Lee

1 LKS Faculty of Medicine, the University of Hong Kong, Department of Medicine, Hong Kong, Hong Kong

Chung Fung Albert Sin

2 LKS Faculty of Medicine, the University of Hong Kong, Department of Pathology, Hong Kong, Hong Kong

Hsin-An Hou

3 National Taiwan University Hospital, Department of Internal Medicine, Taipei, Taiwan

Chih-Cheng Chen

4 Chang-Gung Memorial Hospital, Chiayi, Taiwan College of Medicine, Chang-Gung University, Division of Hematology, Tao-Yuan, Taiwan

Yok Lam Kwong

1 LKS Faculty of Medicine, the University of Hong Kong, Department of Medicine, Hong Kong, Hong Kong